Leesa S.’s Post

View profile for Leesa S., graphic

Managing General Partner @ R3i Capital | Venture Capital | Independent Non Executive Director | Applied AI Investor | Philanthropy | Adjunct Faculty

🚀 Attention Investors and Healthcare Leaders! 🚀 R3i are thrilled to celebrate StratifiCare™ Pte. Ltd.'s CEO, Anthony Chua, who just landed in Dallas, Texas, to accelerate the progress of two revolutionary personalized medicine diagnostics: 🌟 Stratifiden - The world's first severe dengue prognostic that reduces unnecessary hospitalization by 67%, easing the emotional and financial burden on families. 🌟 Stratifirey - The world's first liver cancer diagnostic that predicts patient response to Y90 RE treatment, allowing clinicians to make informed decisions and reduce the agonizing 3 to 6-month wait for results. StratifiCare's journey is a testament to perseverance and innovation. To develop these groundbreaking products, it secured $35M in non-dilutive capital and less than $1M in venture capital. Anthony Chua's unwavering determination teaches us the power of persistence and the impact of every step forward. A special thank you to David Jacobson for welcoming StratifiCare™ Pte. Ltd. into our Texas triangle and the SMU Cox School of Business community. 💡 Investors and hospital administrators, this is your chance to be part of a transformative journey in personalized medicine. Reach out and learn how you can support and benefit from these pioneering advancements. Together let's accelerate impact 💡 NUS Overseas Colleges National University of Singapore Singapore Economic Development Board (EDB) #HealthcareInnovation #PersonalizedMedicine #DengueDiagnostic #LiverCancerDiagnostic #StratifiCare #InvestmentOpportunities #HealthcareLeaders #MedicalBreakthroughs #Valuebasedcare Enterprise Singapore

Solution | StratifiCare | Revolutionalize Dengue Care with Technology

Solution | StratifiCare | Revolutionalize Dengue Care with Technology

stratificare.com

To view or add a comment, sign in

Explore topics